Allogene Therapeutics (NASDAQ: ALLO) revenue
Allogene Therapeutics reported revenue of $2.6m for fiscal 2025, 2,500.0% more than in fiscal 2024 ($0.1m).
Allogene Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 7 was fiscal 2021. The biggest drop was in fiscal 2022, −99.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $2.6m | +2,500.0% | −$209.3m | −8,050.6% |
| 2024 | $0.1m | +5.3% | −$273.2m | −273,199.0% |
| 2023 | $0.1m | −39.1% | −$327.7m | −344,986.3% |
| 2022 | $0.2m | −99.9% | −$335.5m | −215,087.2% |
| 2021 | $114.1m | — | −$180.2m | −157.9% |
| 2020 | $0.0m | — | −$258.2m | — |
| 2019 | $0.0m | — | −$202.0m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Allogene Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Allogene Therapeutics ranks 392nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Allogene Therapeutics, 2,500.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 390th | Absci | $2.8m | −38.2% |
| 391st | Cartesian Therapeutics | $2.8m | −92.8% |
| 392nd | Allogene Therapeutics | $2.6m | 2,500.0% |
| 393rd | Oramed Pharmaceuticals | $2.0m | — |
| 394th | Celldex Therapeutics | $1.5m | −78.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Allogene Therapeutics
- How much revenue did Allogene Therapeutics make in fiscal 2025?
- Allogene Therapeutics reported revenue of $2.6m for fiscal 2025, compared with $0.1m in fiscal 2024.
- What was the best year for revenue at Allogene Therapeutics?
- Of its last 7 fiscal years, fiscal 2021, with $114.1m.
- Where does Allogene Therapeutics rank in its sector by revenue?
- It ranks 392nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Allogene Therapeutics come from?
- From the annual report (Form 10-K) that Allogene Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Allogene Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Allogene Therapeutics: the Allogene Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.